Search Results for keywords:"Curia New York, Inc."

Found 2 results
Skip to main content

Search Results: keywords:"Curia New York, Inc."

  • Type:Notice
    Citation:89 FR 106589
    Reading Time:about a minute or two

    Curia New York, Inc. has applied to the Drug Enforcement Administration (DEA) to become an importer of controlled substances. The company intends to use these substances in bulk manufacturing to produce other controlled substances for their clients. Public feedback on the application can be submitted electronically until January 29, 2025. The application must align with DEA regulations and does not permit importing finished or unfinished drug products for commercial sale.

    Simple Explanation

    Curia New York, Inc. wants government permission to bring in special chemicals to make medicines for other companies. People can tell the government what they think about this until January 29, 2025.

  • Type:Notice
    Citation:89 FR 99827
    Reading Time:less than a minute

    Curia New York, Inc., a subsidiary of Curia Global, Inc., has received authorization to carry out production activities in its location in Rensselaer, New York, which is classified as Subzone 121A of the Foreign-Trade Zone. This authorization follows a notification submitted on August 8, 2024, and a public comment period that was announced in the Federal Register. On December 6, 2024, the FTZ Board decided no further review was needed, allowing Curia New York to proceed with their activities according to the regulations of the FTZ Board.

    Simple Explanation

    Curia New York got the green light to make special ingredients for medicine at their place in New York called Subzone 121A. After checking with the public and making sure everything was okay, they don't need any more approvals to start their work there.